BioStock interview with Åsa Schiött, Chief Scientific Officer at Idogen
Åsa Schiött has headed Idogen’s research and development department in the role of Chief Scientific Officer since September 2020. In an interview with BioStock, Åsa Schiött talks about her background, her first six months at Idogen and the exciting phase of preparing the company's tolerogenic cell therapy for the first clinical trial in patients with severe hemophilia A. Read the interview here For further information, please contact:Anders Karlsson, CEO Idogen ABPhone: +46 (0) 709 18 00 10Email: anders.karlsson@